Stephan Glund
Biberach An Der Riss, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Bioequivalence of Intravenous Alteplase from Two Different Manufacturing Processes in Healthy Male Volunteers: Results from a Two-Stage, Adaptive-Design Study.
Journal: Clinical pharmacokinetics
Published: April 12, 2023
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Journal: Journal of the American College of Cardiology
Published: March 21, 2019
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
Journal: Circulation
Published: December 28, 2018
Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
Journal: Journal of thrombosis and haemostasis : JTH
Published: October 11, 2018
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination.
Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: March 15, 2018
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Journal: The New England journal of medicine
Published: July 12, 2017
Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.
Journal: Research and practice in thrombosis and haemostasis
Published: May 03, 2017
Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet .
Journal: International journal of clinical pharmacology and therapeutics
Published: March 15, 2017
Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
Journal: Clinical pharmacokinetics
Published: December 29, 2016
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
Journal: The American journal of emergency medicine
Published: October 07, 2016
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Journal: The American journal of medicine
Published: August 30, 2016
Last Updated: 09/26/2026